Effects of dopaminergic treatment on bladder function in Parkinson's disease

Neurourology and Urodynamics

Volumn 23, Issue 7, 2004, Pages 689-696

  Winge, Kristian ^a   Werdelin, Lene M ^a   Nielsen, Kurt K ^b   Stimpel, Hans ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Dopamine agents; Micturitional disturbances; Parkinson's disease; Questionnaires; Urodynamics

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER DYSFUNCTION; BLADDER FILLING; BLADDER FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GROUPS BY AGE; HUMAN; MALE; MICTURITION; MICTURITION DISORDER; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PARKINSON DISEASE; SEX DIFFERENCE; URODYNAMICS;

ADULT; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE AGENTS; DOPAMINE AGONISTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; SELEGILINE; SEX CHARACTERISTICS; URINARY BLADDER DISEASES; URINATION DISORDERS; URODYNAMICS; UROLOGIC DISEASES;

EID: 4744353776     PISSN: 07332467     EISSN: None     Source Type: Journal    
DOI: 10.1002/nau.20054     Document Type: Article

References (46)

1. Abrams P, Cardozo L, Fall M, et al. 2003. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 61:37-49.
2. Araki I, Kuno S. 2000. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429-33.
3. Araki I, Kitahara M, Oida T, et al. 2000. Voiding dysfunction and parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 164: 1640-3.
4. Aranda B, Cramer P. 1993. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 12:203-9.
5. Aranda B, Perrigot M, Mazieres L, et al. 1983. Bladder sphincter disorders in Parkinson's disease. Rev Neurol (Paris) 139:283-8.
6. Athwal BS, Berkley KJ, Hussain I, et al. 2001. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 124:369-77.
7. Benson GS, Raezer DM, Anderson JR, et al. 1976. Effect of levodopa on urinary bladder. Urology 7:24-8.
8. Berger Y, Blaivas JG, DeLaRocha ER, et al. 1987. Urodynamic findings in Parkinson's disease. J Urol 138:836-8.
9. Blok BF, Sturms LM, Holstege G. 1997a. A PET study on cortical and subcortical control of pelvic floor musculature in women. J Comp Neurol 389: 535-44.
10. Blok BF, Willemsen AT, Holstege G. 1997b. A PET study on brain control of micturition in humans. Brain 120:111-21.
11. Blok BF, Sturms LM, Holstege G. 1998. Brain activation during micturition in women [see comments]. Brain 121:2033-42.
12. Campos-Sousa RN, Quagliato E, da Silva BB, et al. 2003. Urinary symptoms in Parkinson's disease: Prevalence and associated factors. Arq Neuropsiquiatr 61:359-63.
13. Chai TC, Belville WD, McGuire EJ, et al. 1993. Specificity of the American Urological Association voiding symptom index: Comparison of unselected and selected samples of both sexes. J Urol 150:1710-3.
14. Chandiramani VA, Palace J, Fowler CJ. 1997. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 80:100-4.
15. Christmas TJ, Kempster PA, Chapple CR, et al. 1988. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2:1451-3.
16. Duchesne N, Soucy JP, Masson H, et al. 2002. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clin Neuropharmacol 25:216-24.
17. Escaf S, Cavallotti C, Ricci A, et al. 1994. Dopamine D1 and D2 receptors in the human ureter and urinary bladder: A radioligand binding and autoradiographic study. Br J Urol 73:473-9.
18. Fitzmaurice H, Fowler CJ, Rickards D, et al. 1985. Micturition disturbance in Parkinson's disease. Br J Urol 57:652-6.
19. Gelb DJ, Oliver E, Gilman S. 1999. Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-9.
20. Gray R, Stern G, Malone-Lee J. 1995. Lower urinary tract dysfunction in Parkinson's disease: Changes relate to age and not disease [see comments]. Age Ageing 24:499-504.
21. Hald T, Nordling J, Andersen JT, et al. 1991. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 138:59-62.
22. Hansen BJ, Flyger H, Brasso K, et al. 1995. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 76:451-8.
23. Hansen F, Olsen L, Atan A, et al. 1997. Pressure-flow studies: An evaluation of within-testing reproducibility - Validity of the measured parameters. Neurourol Urodyn 16:521-32.
24. Hansen BJ, Mortensen S, Mensink HJ, et al. 1998. Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group. Br J Urol 81:36-41.
25. Hansen F, Olsen L, Atan A, et al. 1999. Pressure-flow studies: Short-time repeatability. Neurourol Urodyn 18:205-14.
26. Hardoff R, Sula M, Tamir A, et al. 2001. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 16:1041-7.
27. Hattori T, Yasuda K, Kita K, et al. 1992. Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol 46:181-6.
28. Homma Y, Batista J, Bauer S, et al. 2002. Urodynamics. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 2nd International Consultation on Incontinence, 2nd edn. Paris: Health Publication Ltd. pp 317-72.
29. Kay L, Stigsby B, Brasso K, et al. 1999. Lower urinary tract symptoms - A population survey using the Danish Prostatic Symptom Score (DAN-PSS) questionnaire. Scand J Urol Nephrol 33:94-9.
30. Klevmark B. 2002. Volume threshold for micturition. Influence of filling rate on sensory and motor bladder function. Scand J Urol Nephrol Suppl 210:6-10.
31. Lemack GE, Dewey RB, Roehrborn CG, et al. 2000. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 56:250-4.
32. Lepor H, Machi G. 1993. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 42:36-40.
33. Mattay VS, Tessitore A, Callicott JH, et al. 2002. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51:156-64.
34. Moller LA, Lose G, Jorgensen T. 2000. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet Gynecol Scand 79:298-305.
35. Nour S, Svarer C, Kristensen JK, et al. 2000. Cerebral activation during micturition in normal men. Brain 123:781-9.
36. Pavlakis AJ, Siroky MB, Goldstein I, et al. 1983. Neurourologic findings in Parkinson's disease. J Urol 129:80-3.
37. Sakakibara R, Shinotoh H, Uchiyama T, et al. 2001a. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 92:76-85.
38. Sakakibara R, Shinotoh H, Uchiyama T, et al. 2001b. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 187:55-9.
39. Schatzl G, Temml C, Waldmuller J, et al. 2001. A comparative cross-sectional study of lower urinary tract symptoms in both sexes. Eur Urol 40:213-9.
40. Seki S, Igawa Y, Kaidoh K, et al. 2001. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 20:105-13.
41. Uchiyama T, Sakakibara R, Hattori T, et al. 2003. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 18:573-8.
42. Winge K, Werdelin LM, Krøyer K, et al. 2002. Bladder Dysfunction in young patients with Parkinson's Disease [abstract]. Mov Disord 17:s218.
43. Winge K, Rasmussen D, Werdelin LM. 2003. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry 74:13-9.
44. Yamamoto M. 1997. Pergolide improves neurogenic bladder in patients with Parkinson's disease. Mov Disord 12:328.
45. Yoshimura N, Mizuta E, Kuno S, et al. 1993. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32:315-21.
46. Yoshimura N, Mizuta E, Yoshida O, et al. 1998. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 286:228-33.